Nkarta to Participate in Upcoming Investor Conferences
April 03, 2024 16:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Announces Pricing of $240 Million Underwritten Offering
March 25, 2024 06:30 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the...
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
March 21, 2024 16:01 ET
|
Nkarta, Inc.
First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated autoimmune diseases under...
Nkarta to Participate in Upcoming Investor Conferences
February 28, 2024 08:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
December 09, 2023 20:31 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 09, 2023 16:02 ET
|
Nkarta, Inc.
FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune diseaseNKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease...
Nkarta to Participate at Upcoming Investor Conferences
November 07, 2023 08:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
October 17, 2023 07:01 ET
|
Nkarta, Inc.
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell...
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
October 16, 2023 16:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that...
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 10, 2023 07:01 ET
|
Nkarta, Inc.
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and...